New opportunity for orphan drug development in Japan: Early exploratory clinical trial bases promote drug translation from basic studies to clinical application.
暂无分享,去创建一个
Jianjun Gao | P. Song | N. Kokudo | W. Tang
[1] Jianjun Gao,et al. Intractable and rare diseases research in Asia. , 2012, Bioscience trends.
[2] T. Takeuchi,et al. CD3 ζ defects in systemic lupus erythematosus , 2012, Annals of the rheumatic diseases.
[3] Jianjun Gao,et al. Rare diseases, orphan drugs, and their regulation in Asia: Current status and future perspectives. , 2012, Intractable & rare diseases research.
[4] H. Ogata,et al. Ectopic expression of blood type antigens in inflamed mucosa with higher incidence of FUT2 secretor status in colonic Crohn’s disease , 2011, Journal of Gastroenterology.
[5] E. Tambuyzer,et al. Rare diseases, orphan drugs and their regulation: questions and misconceptions , 2010, Nature Reviews Drug Discovery.
[6] Takeshi Iwatsubo,et al. Japanese Alzheimer's Disease Neuroimaging Initiative: Present status and future , 2010, Alzheimer's & Dementia.
[7] K. Tsutani,et al. Personal imports of drugs to Japan in 2005 – an analysis of import certificates , 2008, Journal of Clinical Pharmacy and Therapeutics.
[8] D. Phillips,et al. The Present Status and the Future , 1993 .